Novartis' deal on COPD compound AD 237, co-developed by Vectura and Arakis, proves that low-risk "re-profilers" can win big bucks. But the program must be right, and so must the partner's portfolio. It isn't about the technology-it's about the product.
By Melanie Senior
Re-profilers rejoice. Your jumpstart model has been vindicated.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
